I-Mab (IMAB) Competitors $1.07 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IMAB vs. MGTX, TSHA, ORGO, VYGR, RNAC, FATE, SNDL, AMLX, YSB, and CYRXShould you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include MeiraGTx (MGTX), Taysha Gene Therapies (TSHA), Organogenesis (ORGO), Voyager Therapeutics (VYGR), Cartesian Therapeutics (RNAC), Fate Therapeutics (FATE), SNDL (SNDL), Amylyx Pharmaceuticals (AMLX), YS Biopharma (YSB), and Cryoport (CYRX). These companies are all part of the "pharmaceutical products" industry. I-Mab vs. MeiraGTx Taysha Gene Therapies Organogenesis Voyager Therapeutics Cartesian Therapeutics Fate Therapeutics SNDL Amylyx Pharmaceuticals YS Biopharma Cryoport I-Mab (NASDAQ:IMAB) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings. Which has stronger earnings & valuation, IMAB or MGTX? MeiraGTx has higher revenue and earnings than I-Mab. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioI-Mab$3.89M22.40-$206.44MN/AN/AMeiraGTx$14.02M26.90-$84.03M-$1.40-4.15 Is IMAB or MGTX more profitable? I-Mab has a net margin of 0.00% compared to MeiraGTx's net margin of -1,146.81%. I-Mab's return on equity of 0.00% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets I-MabN/A N/A N/A MeiraGTx -1,146.81%-152.82%-56.41% Do institutionals and insiders believe in IMAB or MGTX? 38.4% of I-Mab shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 8.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, IMAB or MGTX? I-Mab has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Does the media prefer IMAB or MGTX? In the previous week, I-Mab had 3 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for I-Mab and 0 mentions for MeiraGTx. I-Mab's average media sentiment score of 0.10 beat MeiraGTx's score of 0.00 indicating that I-Mab is being referred to more favorably in the media. Company Overall Sentiment I-Mab Neutral MeiraGTx Neutral Does the MarketBeat Community favor IMAB or MGTX? MeiraGTx received 131 more outperform votes than I-Mab when rated by MarketBeat users. Likewise, 71.32% of users gave MeiraGTx an outperform vote while only 63.74% of users gave I-Mab an outperform vote. CompanyUnderperformOutperformI-MabOutperform Votes5863.74% Underperform Votes3336.26% MeiraGTxOutperform Votes18971.32% Underperform Votes7628.68% Do analysts rate IMAB or MGTX? I-Mab presently has a consensus price target of $8.00, suggesting a potential upside of 647.66%. MeiraGTx has a consensus price target of $22.50, suggesting a potential upside of 287.26%. Given I-Mab's higher possible upside, research analysts clearly believe I-Mab is more favorable than MeiraGTx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryI-Mab beats MeiraGTx on 8 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAB vs. The Competition Export to ExcelMetricI-MabPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.13M$7.02B$5.31B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E RatioN/A9.71115.5615.17Price / Sales22.40396.471,498.5592.39Price / CashN/A47.4339.6734.18Price / Book0.375.604.765.07Net Income-$206.44M$153.56M$118.47M$225.38M7 Day Performance-9.32%-1.45%-0.38%0.07%1 Month Performance-12.30%15.33%6.05%3.96%1 Year Performance-30.07%43.25%38.18%32.54% I-Mab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMABI-Mab3.3508 of 5 stars$1.07flat$8.00+647.7%-30.1%$87.14M$3.59M0.0034News CoverageMGTXMeiraGTx4.4545 of 5 stars$5.86+1.0%$22.50+284.0%+15.3%$380.31M$14.02M-4.19300TSHATaysha Gene Therapies1.6547 of 5 stars$1.99+1.0%$6.38+220.4%-35.8%$372.17M$12.87M-9.95180News CoverageORGOOrganogenesis4.0766 of 5 stars$2.80-2.4%$4.88+74.1%+21.4%$371.20M$448.39M-21.54950News CoverageVYGRVoyager Therapeutics4.2127 of 5 stars$6.75+2.6%$17.43+158.2%+6.9%$367.16M$143.77M24.11100Upcoming EarningsAnalyst UpgradeRNACCartesian Therapeutics3.3474 of 5 stars$20.58-6.9%$43.00+108.9%N/A$366.24M$54.10M0.0037Positive NewsFATEFate Therapeutics3.633 of 5 stars$2.65-5.7%$6.90+160.4%+25.9%$363.27M$63.53M-1.55550Short Interest ↑Gap UpSNDLSNDL3.3274 of 5 stars$2.18+3.3%$3.63+66.3%+46.5%$361.92M$911.92M-6.812,516Upcoming EarningsAMLXAmylyx Pharmaceuticals4.0918 of 5 stars$5.31+8.4%$14.57+174.4%-67.0%$361.11M$298.76M-2.17200Positive NewsYSBYS Biopharma1.4561 of 5 starsN/A$5.25+∞N/A$344.32M$560.76M0.00773CYRXCryoport2.515 of 5 stars$6.89+2.2%$12.00+74.2%-24.9%$339.38M$225.61M-1.881,170Upcoming EarningsShort Interest ↑News Coverage Related Companies and Tools Related Companies MeiraGTx Alternatives Taysha Gene Therapies Alternatives Organogenesis Alternatives Voyager Therapeutics Alternatives Cartesian Therapeutics Alternatives Fate Therapeutics Alternatives SNDL Alternatives Amylyx Pharmaceuticals Alternatives YS Biopharma Alternatives Cryoport Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMAB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
